BioMedNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) Colleague Receives 2021 International Dupuytren Award

180 Life Sciences Corp. (NASDAQ: ATNF), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, has announced that Dr. Lynn Williams, PhD, has received the International Dupuytren Award 2021 for Basic Research. Williams’s research is sponsored by 180 Life Sciences. The award was given for research conducted by and a paper written by Williams. The paper, which was published in “Proceedings of the National Academy of Science, USA,” was titled “Identifying collagen VI as a target of fibrotic diseases regulated by CREBBP/EP300.” The research identified the collagen VI pathway, which 180 Life Sciences is now pursuing in preclinical studies. The findings reported in the paper were compiled as a result of Williams’s work as a member of Professor Jagdeep Nanchahal’s research team; Nanchahal is chairman of 180 Life Sciences’ Clinical Advisory Board. The announcement noted that Dr. Thomas Layton, another member of Nanchahal’s research team in Oxford, was named as a joint  recipient of the International Dupuytren Award in both 2020 and 2019. Nanchahal and his clinical research team received the 2019 award for the publication of the phase 2a clinical trial data. “This pivotal research for which Dr. Williams has received this award, was published in a high-impact journal and provides insight into Collagen VI pathways to identify novel potential therapeutic targets for fibrotic diseases,” said 180 Life Sciences CEO James Woody in the press release. “This research from our team, led by Professor Jagdeep Nanchahal, is the foundation of our program to develop new treatments for fibrosis.”

To view the full press release, visit https://ibn.fm/1LF2E

About 180 Life Sciences Corp.

180 Life Sciences is a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. 180 Life Sciences is leading the research into solving one of the world’s biggest drivers of disease — inflammation. The company is driving groundbreaking studies into clinical programs, which are seeking to develop novel drugs addressing separate areas of inflammation for which there are no effective therapies. 180 Life Sciences’s primary platform is a novel program to treat fibrosis using anti-TNF (“TNF”) (tumor necrosis factor), with its lead program in phase 2b/3 clinical trials. For more information about the company, visit www.180LifeSciences.com.

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]

BioMedWire is part of the InvestorBrandNetwork